Last reviewed · How we verify
Matching Placebo for Ibuprofen
This is an inert placebo formulation designed to match the appearance and administration of ibuprofen for use as a control in clinical trials.
This is an inert placebo formulation designed to match the appearance and administration of ibuprofen for use as a control in clinical trials. Used for Control arm in phase 3 clinical trials for ibuprofen efficacy and safety.
At a glance
| Generic name | Matching Placebo for Ibuprofen |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A matching placebo contains no active pharmaceutical ingredient and is used in blinded clinical trials to control for placebo effect and bias. It is formulated to be indistinguishable from the active ibuprofen comparator in appearance, taste, and administration route, allowing researchers to isolate the true therapeutic effect of ibuprofen from psychological and contextual factors.
Approved indications
- Control arm in phase 3 clinical trials for ibuprofen efficacy and safety
Common side effects
Key clinical trials
- Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression (PHASE1, PHASE2)
- A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057) (PHASE2)
- Ibuprofen With or Without Acetaminophen for Low Back Pain (PHASE3)
- Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098) (PHASE3)
- Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe) (PHASE4)
- Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States) (PHASE4)
- Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen (PHASE4)
- Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo for Ibuprofen CI brief — competitive landscape report
- Matching Placebo for Ibuprofen updates RSS · CI watch RSS
- Organon and Co portfolio CI